Sanofi and have received split decision from an advisory panel to the US Food and Drug Administration (FDA) on whether to recommend diabetes drug Zynquista (sotagliflozin) for approval.
Jointly developed by the companies, sotagliflozin is an investigational, oral dual SGLT1 and SGLT2 inhibitor being reviewed as an adjunct therapy to insulin for adults living with type 1 diabetes.
The committee was split eight to eight when voting if the overall benefits of the drug outweighed the associated risks.
Sanofi Diabetes Medical Affairs global vice-president and head Rachele Berria said: 鈥淲e believe in the overall benefit-risk profile of sotagliflozin for adults with type 1 diabetes who lack adequate glycemic control using insulin alone.
鈥淲e will continue to work with the FDA through its review process to hopefully bring to patients a new treatment that can help people living with type 1 diabetes control their blood sugar and address some of the challenges of insulin-only therapy.鈥�
The new drug application submitted to the regulatory agency included results from the inTandem clinical trial programme of sotagliflozin.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataUnder the programme, three Phase III clinical trials were conducted to evaluate the safety and efficacy of the drug in nearly 3,000 adults with inadequately controlled type-1 diabetes.
According to Reuters, trial participants who attended the panel meeting were in favour of the drug鈥檚 effectiveness, but FDA staff identified the risk of diabetic ketoacidosis (DKA).
The news agency added that Sanofi and Lexicon proposed a risk evaluation and mitigation strategy (REMS) to educate patients and physicians. Besides, patients using the drug will be required to undergo regular ketone level testing.
Panel member Rebecca Brown was quoted by Reuters as saying: 鈥淭he task going forward will be to have a REMS strategy that will effectively select and maintain the patients and providers who can use this drug in the safest way possible.鈥�
The FDA is not obligated to adhere to the committee鈥檚 vote, but it does take note of the panel鈥檚 recommendations. The regulatory agency is scheduled to make its decision on sotagliflozin by 22 March this year.
